Synergism from combinations of platinums in the human ovarian tumour models
Alamro A
School of Medical Sciences, Sydney Medical School, The University of Sydney
Abstract:
Cisplatin and its analogue carboplatin are two of the most widely used anticancer drugs. With the aim of reducing the side-effects and widening the spectrum of activity, thousands of cisplatin analogues have been prepared by changing the nature of the leaving groups and the carrier ligands. Although it has been possible to greatly reduce the side-effects, only a limited change in spectrum of activity has been achieved, because of inherent or acquired resistance.
Combination of drugs with different modes of action that may act synergistically can offer a means of overcoming drug resistance and reducing the side effects. Although the antitumor activity of platinum drugs are believed to be associated with their binding with the DNA, the actual nature of nature of interaction of the rule-breaker platinums may differ from that of cisplatin analogues. Hence the rule-breaker platinums may act synergistically in combination with cisplatin. In this study, synergism from combinations of five trans-planaramineplatinum(II) complexes, coded as YH11, YH12 of the form trans-PtL(NH3)Cl2, where L=3-hydroxypyridine and imidazo(1,2-a)pyridine, CH1, CH2 and DH3, of the form trans-PtCl2L2, where L=3-hydroxypyridine, 4-hydroxypyridine, 2-hydroxypyridine in human ovarian tumour models are investigated using three different sequences of administration 0/0 h, 0/2 h and 2/0 h. Further studies on combinations of cisplatin, transplatinums and Egcg (the main antioxidant found in green tea) are also done.
In this poster we will report the results on the combinations of cisplatin with trans-platinums in human ovarian tumour models.
